Clinical trials in Le Chesnay-Rocquencourt – page 32

3 344 clinical trials in Le Chesnay-Rocquencourt, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in FranceEssaisCliniques.fr

Le Chesnay-Rocquencourt at a glance

3 344

clinical trials

Research sites1

Quick filters

3 344 trials in Le Chesnay-Rocquencourt

Open in trial search

Non-small cell lung cancer stage IIIA+2

Recruiting

Testing MK-2870 with pembrolizumab compared to pembrolizumab alone after surgery in patients with non-small cell lung cancer who did not respond fully to treatment

Registered drugNo placebo

Testing MK-2870 with pembrolizumab compared to pembrolizumab alone after surgery in patients with non-small cell lung cancer who did not respond fully to treatment

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Myasthenia gravis

Recruiting

Study of oral cladribine compared to placebo for patients with generalized myasthenia gravis

Registered drug

Study of oral cladribine compared to placebo for patients with generalized myasthenia gravis

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Cladribine
Sponsor:Merck Healthcare KGaA

Contact Research Centre

Hyperkalaemia

Recruiting

A study testing how well patiromer lowers high potassium levels in the blood in children under 12 years of age with hyperkalemia

InvestigationalNo placebo

A study testing how well patiromer lowers high potassium levels in the blood in children under 12 years of age with hyperkalemia

InvestigationalNo placebo

France

Participants:0–17 years
Substances:Patiromer
Sponsor:Vifor Pharma Inc.

Contact Research Centre

Hypergammaglobulinaemia benign monoclonal+1

Recruiting

A Study of Linvoseltamab in Adult Patients with High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma

Registered drugNo placebo

A Study of Linvoseltamab in Adult Patients with High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Dexamethasone
Sponsor:Regeneron Pharmaceuticals Inc.

Contact Research Centre

Triple negative breast cancer

Recruiting

Study comparing datopotamab deruxtecan with or without durvalumab to chemotherapy with pembrolizumab for patients with triple-negative breast cancer

Registered drugNo placebo

Study comparing datopotamab deruxtecan with or without durvalumab to chemotherapy with pembrolizumab for patients with triple-negative breast cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:AstraZeneca AB

Contact Research Centre

Follicle centre lymphoma follicular grade I, II - III

Recruiting

A study comparing odronextamab combined with chemotherapy versus rituximab combined with chemotherapy in adults with previously untreated follicular lymphoma

Registered drugNo placebo

A study comparing odronextamab combined with chemotherapy versus rituximab combined with chemotherapy in adults with previously untreated follicular lymphoma

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Cyclophosphamide
Sponsor:Regeneron Pharmaceuticals Inc.

Contact Research Centre

Neoplasm malignant+2

Recruiting

A study of EP0031 and drug combination for patients with advanced cancers having changes in the RET gene

Registered drugNo placebo

A study of EP0031 and drug combination for patients with advanced cancers having changes in the RET gene

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Ellipses Pharma Limited

Contact Research Centre

Neoplasm malignant

Recruiting

A study of DT-7012 alone and in combination with pembrolizumab in patients with advanced solid tumors

InvestigationalNo placebo

A study of DT-7012 alone and in combination with pembrolizumab in patients with advanced solid tumors

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:DT-7012
Sponsor:Domain Therapeutics Australia Pty Limited

Contact Research Centre

Non-small cell lung cancer

Recruiting

A Study of Telisotuzumab Adizutecan Compared to Standard Treatment in Adults with Advanced Non-Small Cell Lung Cancer After Previous Treatment

Registered drugNo placebo

A Study of Telisotuzumab Adizutecan Compared to Standard Treatment in Adults with Advanced Non-Small Cell Lung Cancer After Previous Treatment

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Amivantamab
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Myasthenia gravis

Recruiting

A study testing how inebilizumab works and how safe it is in children and teenagers aged 2 to 17 years with generalized myasthenia gravis

Registered drugNo placebo

A study testing how inebilizumab works and how safe it is in children and teenagers aged 2 to 17 years with generalized myasthenia gravis

Registered drugNo placebo

France

Participants:0–17 years
Substances:Inebilizumab
Sponsor:Amgen Inc.

Contact Research Centre

B-cell type acute leukaemia

Recruiting

Study of chemotherapy with blinatumomab and tyrosine kinase inhibitors in newly diagnosed children and young adults with Philadelphia chromosome positive B-cell acute lymphoblastic leukemia

Registered drugNo placebo

Study of chemotherapy with blinatumomab and tyrosine kinase inhibitors in newly diagnosed children and young adults with Philadelphia chromosome positive B-cell acute lymphoblastic leukemia

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years
Substances:Blinatumomab
Sponsor:Universita Degli Studi Di Milano Bicocca

Contact Research Centre

Chronic inflammatory demyelinating polyradiculoneuropathy

Recruiting

A study to test if empasiprubart can improve function and is safe for adults with chronic inflammatory demyelinating polyneuropathy

Investigational

A study to test if empasiprubart can improve function and is safe for adults with chronic inflammatory demyelinating polyneuropathy

Investigational

France

Participants:18–64 years · 65+ years
Sponsor:Argenx

Contact Research Centre

Other cities in France

The busiest research cities in the country

All 366 cities in France

Clinical research in Le Chesnay-Rocquencourt

What the registry says about research in the country

01 Cardiology & Respiratory Medicine

Clinical trials focusing on acute myocardial infarction pain management and innovative treatments for severe asthma. Research includes evaluation of novel pain-relief methods and assessment of treatment discontinuation strategies.

Pain management in heart attacks
Asthma treatment optimization
Heart failure management

Studies also examine beta-blocker discontinuation in patients with recovered heart function.

02 Oncology & Hematology

Extensive research in blood cancers, including multiple myeloma, acute myeloid leukemia, and various lymphomas. Studies evaluate novel drug combinations and treatment strategies.

Blood cancer therapies
Leukemia treatments
Breast cancer management

Investigations include targeted therapies and personalized treatment approaches for various cancer types.

03 Pediatric & Infectious Diseases

Research focusing on respiratory syncytial virus (RSV) prevention in infants and children. Studies evaluate new protective treatments and their safety profiles.

RSV prevention
Infant protection studies
Immunotherapy research

Trials include assessment of novel medications for preventing severe respiratory infections in vulnerable populations.

Back to France All countries